Background: Some gastric diffuse large B-cell lymphomas have been reported to regress completely after the successful eradication of Helicobacter pylori. The aim of this study was to investigate the clinical characteristics of gastric diffuse large B-cell lymphomas without any detectable mucosa-associated lymphoid tissue (MALT) lymphoma that went into complete remission after successful H. pylori eradication. Patients and Methods:We examined the effect of H. pylori eradication in 15 H. pylori-positive gastric diffuse large B-cell lymphoma patients without any evidence of an associated MALT lymphoma (clinical stage I by the Lugano classification) by endoscopic examination including biopsies, endoscopic ultrasonography, computed tomography, and bone marrow aspiration. Results: H. pylori eradication was successful in all the patients and complete remission was achieved in four patients whose clinical stage was I. By endoscopic examination, these gastric lesions appeared to be superficial. The depth by endoscopic ultrasonography was restricted to the mucosa in two patients and to the shallow portion of the submucosa in the other two patients. All four patients remained in complete remission for 7-100 months. Conclusion: In gastric diffuse large B-cell lymphomas without a concomitant MALT lymphoma but associated with H. pylori infection, only superficial cases and lesions limited to the shallow portion of the submucosa regressed completely after successful H. pylori eradication. The endoscopic appearance and the rating of the depth of invasion by endosonography are both valuable for predicting the efficacy of H. pylori eradication in treating gastric diffuse large B-cell lymphomas.

Hypofractionated IFRT with weekly CBDCA/PTX was a feasible treatment regimen. Hypofractionated IFRT with a total dose of 67.5 Gy or more could be a promising modality to improve the treatment results in patients with locally advanced NSCLC.

The interaction between the cytotoxic effect of bleomycin (BLM) or cis-diamminedichloroplatinum(II) (cis-DDP) and the kinetics of thermotolerance was studied in cultured Chinese hamster ovary (CHO) cells. Pre-heated cells were treated with cis-DDP or BLM at 37 or 43 degrees C for various times after heating. Pre-heating enhanced cis-DDP cytotoxicity given immediately after heating, but this enhancement decreased within 24 h to an additive level. Cell survival following the initial heating and the second treatment of 'cis-DDP at 43 degrees C was minimal when cis-DDP at 43 degrees C was given immediately after the initial heating, but became higher with increasing treatment interval and reached 'less than additive' level when the treatment interval was extended to more than 24 h. This alteration in cell survival appeared to follow the kinetics of thermotolerance. The interaction between BLM treatment and the kinetics of thermotolerance was similar to that of cis-DDP. However, pre-heating enhanced BLM cytotoxicity much less extensively than cis-DDP cytotoxicity. These results indicate that: (a) pre-heating of cells enhanced drug-toxicity when the drug was given shortly after heating, but the magnitude of this enhancement depended on the drug; (b) pre-heating did not influence the cytotoxicity of drugs given at 37 degrees C; and (c) pre-heating decreased the magnitude of thermal sensitization of drug cytotoxicity. The magnitude of the decrease in thermal sensitization appeared to be parallel to the kinetics of thermotolerance. In this study it was also demonstrated that pre-treatment of CHO cells by cis-DDP or BLM did not alter sensitivity to subsequent drug treatment, hyperthermia or thermochemotherapy.

Purpose This study aimed to evaluate the relationship between chronic kidney disease (CKD) after radiation therapy for gastric/duodenal mucosa-associated lymphoid tissue lymphoma and dose-volume histogram of the kidneys. Methods and Materials We retrospectively reviewed 40 patients who received 3-dimensional conformal radiation therapy. CKD was evaluated using the Common Terminology Criteria for Adverse Events version 5.0. The mean dose of bilateral kidneys/right kidney/left kidney (D mean of b-kidneys ) (D mean of r-kidney ) (D mean of l-kidney ), bilateral kidneys/right kidney/left kidney volume receiving ≥ x Gy (V x of b-kidneys ) (V x of r-kidney ) (V x of l-kidney ), and patients’ baseline clinical characteristics were analyzed. Results The median radiation therapy dose was 28 (range, 24-44.8) Gy in 14 fractions. The median follow-up period was 63.1 months, and the 5-year cumulative incidence of grade 2 CKD rate was 14.8%. Among several factors, V 5 of b-kidneys was most strongly associated with grade 2 or worse CKD, with an area under the curve of 0.81 in the receiver operating characteristic curve. The 5-year incidence rate in patients with V 5 of b-kidneys ≥ 58% was significantly higher than that in other patients (24.5% and 9.8%, respectively; P < .05). Conclusions In this study using 3-dimensional conformal radiation therapy, the rate of adverse events at 5 years was low, many patients showed toxicity after 5 years; thus, continuous follow-up is necessary to detect potential nephrotoxicity. Our data demonstrate that V 5 of b-kidneys was most strongly associated with the risk of CKD. With lower doses and more advanced techniques in recent years, the incidence of CKD may be further reduced.

multiregional primary site (OR 0.66 vs. HN) were less likely to receive RT alone. Among patients treated with CMT, the majority (64.6%) received 30 to 36 Gy, while 19.1% received >20 to <30 Gy, 7.3% received exactly 20 Gy, 4.6% received >36 Gy, and 4.4% received <20 Gy. The use of 20 Gy was more common at academic facilities (11% vs. 7-9% at other facilities) and increased significantly after 2010, with rates of 1-9% in 2004-2009 and 9-17% in 2010-2015. Adjusting for competing variables, use of 20 Gy (vs. 30 to 36 Gy) was less common for thorax site (OR 0.43 vs. HN), stage II disease (OR 0.41), B symptoms (OR 0.33), and Medicaid or uninsured patients (OR 0.70 and 0.52, respectively vs. private insurance). 20 Gy dosing was more common with increasing distance from treatment center (OR 2.9 for >100 miles) and later year of diagnosis (OR 6.3 for 2010-2015 vs 2004-2009). Use of dose >36 Gy decreased over time (4-9% in 2004-2009 vs 2-4% in 2010-2015). Conclusion: Of patients receiving RT for early stage HL, 12% receive RT alone. Adjusting for co-variates, RT alone (vs. CMT) is more common among patients with NLPHL, older age, black race, and axilla or groin disease, but less common in those with B symptoms, stage II disease, and thoracic disease. Of those treated with CMT, there is a wide variability in RT dose. The use of 20 Gy is increasing since 2010 and is more common in patients with stage I disease, no B symptoms, HN site, academic facility, and greater distance from facility.